The weekend and Friday PRs to explain the BLA misstatement hurt investor confidence. It is a shame because all indications are this drug has SO much potential. ***The best product does not always come out as the winner. Marketing, execution and strategic planning have dictated product winners more than the product itself.

I would prefer less PRs with more accuracy, CytoDyn's PR strategy wreaks of pump dump.

You pair that with all of the shares added and questions about whether our CEO exercised and sold right before this information came out that BLA was not filed after all.. It REALLY says scam which is a shame. Not saying it is but look at it from an objective outside investors perspective....